共 50 条
- [31] Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational StudyDrugs in R&D, 2021, 21 : 351 - 357Hiroki WakabayashiNobuto NagaoHitoshi InadaYosuke NishiokaMasahiro HasegawaKusuki NishiokaAkihiro Sudo
- [32] Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational StudyDRUGS IN R&D, 2021, 21 (03) : 351 - 357Wakabayashi, HirokiNagao, NobutoInada, HitoshiNishioka, YosukeHasegawa, MasahiroNishioka, KusukiSudo, Akihiro
- [33] Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free statusANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (11) : 1497 - 1504Boeters, Debbie M.Burgers, Leonie E.Toes, Rene E. M.van der Helm-van Mil, Annette
- [34] DOES IMMUNOLOGICAL REMISSION, DEFINED AS DISAPPEARANCE OF AUTOANTIBODIES, OCCUR WITH CURRENT TREATMENT STRATEGIES? A LONG-TERM FOLLOW-UP STUDY IN RHEUMATOID ARTHRITIS PATIENTS WHO ACHIEVED A SUSTAINED DMARD-FREE STATUSANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 256 - 257Boeters, DebbieBurgers, LeonieToes, Renevan der Helm-van Mil, Annette
- [35] Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyLEUKEMIA, 2020, 34 (03) : 787 - 798Burger, Jan A.Barr, Paul M.Robak, TadeuszOwen, CarolynGhia, PaoloTedeschi, AlessandraBairey, OsnatHillmen, PeterCoutre, Steven E.Devereux, StephenGrosicki, SebastianMcCarthy, HelenSimpson, DavidOffner, FritzMoreno, CarolDai, SandraLal, InduDean, James P.Kipps, Thomas J.
- [36] Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyLeukemia, 2020, 34 : 787 - 798Jan A. BurgerPaul M. BarrTadeusz RobakCarolyn OwenPaolo GhiaAlessandra TedeschiOsnat BaireyPeter HillmenSteven E. CoutreStephen DevereuxSebastian GrosickiHelen McCarthyDavid SimpsonFritz OffnerCarol MorenoSandra DaiIndu LalJames P. DeanThomas J. Kipps
- [37] Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNFα antibody therapyJOURNAL OF CLINICAL IMMUNOLOGY, 1999, 19 (05) : 305 - 313Ohshima, SSaeki, YMima, TSasai, MNishioka, KIshida, HShimizu, MSuemura, MMcCloskey, RKishimoto, T
- [38] Long-Term Follow-Up of the Changes in Circulating Cytokines, Soluble Cytokine Receptors, and White Blood Cell Subset Counts in Patients with Rheumatoid Arthritis (RA) After Monoclonal Anti-TNFα Antibody TherapyJournal of Clinical Immunology, 1999, 19 : 305 - 313Shiro OhshimaYukihiko SaekiToru MimaMitsuko SasaiKatsuhiro NishiokaHiroshi IshidaMasatoshi ShimizuMasaki SuemuraRichard McCloskeyTadamitsu Kishimoto
- [39] EFFICACY AND SAFETY OF TABALUMAB, AN ANTI-B CELL ACTIVATING FACTOR MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN INADEQUATE RESPONSE TO TNF-ALPHA INHIBITORS: RESULTS FROM A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDYANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 952 - 953Schiff, M.Combe, B.Doerner, T.Kremer, J. M.Huizinga, T. W.Veenhuizen, M.Gill, A.Zou, H.Komocsar, W.Berclaz, P. -Y.Ortmann, R.Lee, C.
- [40] LONG-TERM COST-UTILITY ANALYSIS OF TREATMENT STRATEGIES IN PATIENTS WITH RECENT-ONSET RHEUMATOID ARTHRITIS-5 YEAR FOLLOW-UP DATA FROM THE BEST STUDYANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 363 - 364van den Hout, W.Klarenbeek, N.Dirven, L.Kerstens, P.Huizinga, T.Lems, W.Allaart, C.